Navigation Links
Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
Date:12/10/2010

NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia).  In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

Pfizer's decision was based on a review of emerging safety information from clinical trials and post-marketing reports.  While liver toxicity is a known complication of the class of drugs to which Thelin belongs, a new potentially life-threatening idiosyncratic risk of liver injury with Thelin has been observed. Given the availability of alternate treatments, Pfizer has concluded that the overall benefit of Thelin no longer outweighs the risk in the general population of PAH patients.  The Company has notified health authorities about this finding and its decision to voluntarily withdraw Thelin from the market and stop clinical studies.  

"Pfizer's priority is to ensure the safety and well-being of patients, and we are in the process of communicating all of this information to the appropriate medical professionals and regulatory authorities in all regions as quickly as possible," said Cara Cassino, MD, vice president, Clinical Development and Medical Affairs for Pfizer's Pulmonary Vascular Disease unit.

Pfizer recommends that no new patients be prescribed Thelin and that patients receiving Thelin be transitioned to appropriate alternate therapies as soon as safely possible according to best local practice.  Patients taking Thelin or participating in Thelin studies are advised to consult with their health care professional as soon as possible.  Patients should not stop takin
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biovista Announces a Drug Repositioning Collaboration With Pfizer
2. MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
3. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
4. Pfizer Wins CIO 100 Award for Patient Enrollment Optimization Solution From DecisionView
5. Pfizer Announces EMPHASIS-HF Trial to Halt Recruitment due to Significant Benefit Observed in Patients Treated With Inspra® (Eplerenone)
6. Pfizer Animal Health Expands Global Commitment to a Safe Food Supply with a New Focus on Healthy Fish
7. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
8. Pfizer Global Manufacturing Announces Plans to Reconfigure Its Global Plant Network
9. Anavex comments on failure of Pfizer and Medivations Alzheimers investigational drug Dimebon during Phase 3 clinical trials
10. Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting
11. Pfizer Global R&D Presents 2008 Top Intermediates CMO Award to Asymchem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
(Date:1/14/2014)... January 14, 2014 Independent publisher Bitingduck ... and Montreal, Canada, has big ideas for 2014 in ... press's goals are to produce high-quality, low-cost, DRM-free ebooks ... local businesses. , The first major development will ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... 12 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... and,nine months ended Sept. 30, 2007. Third ... for the third quarter and nine months ended ... respectively, compared with $16.5 million,and $30.2 million, respectively, ...
... Fla., Nov. 12 GeoPharma, Inc. (Nasdaq:,GORX) (the ... an,approval from the FDA to begin producing Carprofen. ... is a,non-steroidal anti-inflammatory drug (NSAID) that is used ... associated with osteoarthritis in,dogs. Additionally, Carprofen is often ...
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
Cached Biology Technology:Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 2Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 3Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 4Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 5Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results 6GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 2GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen 3BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3
(Date:4/17/2014)... the process whereby the genetic information of DNA ... proteins, which have numerous different functions in living ... intermediary during gene expression, by relating the genetic ... in manufacturing proteins. , By examining the ... in an organism at a given time, researchers ...
(Date:4/17/2014)... National University (ANU), have developed a new way ... over the past 5.3 million years., The findings ... ice ages over the past two million years, ... dioxide levels, global temperatures and sea levels., The ... and the National Oceanography Centre (NOC) in the ...
(Date:4/16/2014)... collections two new species of yellow-shouldered bats have been unearthed by ... Museum of Natural History and described in the open access journal ... genus Sturnira are part of a recent discovery of ... one still waiting to be officially announced. , Up until recently ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Ancient sea-levels give new clues on ice ages 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... and bees may do it, but the microscopic animals called ... thank you. Whats more, they have done so over millions ... These hardy creatures somehow escape the usual drawback of asexuality ... Meselson, and their colleagues are finding out how. ...
... to permanent paralysis and loss of sensation below the site ... The nerve fibers or axons have the capacity to grow ... develops around the injury. Northwestern University researchers have ... of scar tissue at the injury site and enables the ...
... available in French . , Modern ... of the worlds water flows, with potentially sudden and ... them researchers at the Stockholm University-affiliated Stockholm Resilience Centre ... published April 1 in the journal Trends in Ecology ...
Cached Biology News:Is DNA repair a substitute for sex? 2Is DNA repair a substitute for sex? 3Promising new nanotechnology for spinal cord injury 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 2Sudden 'ecosystem flips' imperil world's poorest regions, say water experts 3
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
interferon-related developmental regulator 2...
Biology Products: